Experimental Sjögren’s therapy shows potential in early lab studies
KB-7898, Kronos Bio’s investigational therapy for Sjögren’s disease, was shown to lower antibody production and the release of inflammatory molecules in lab studies involving cell and animal models of autoimmune conditions, the company announced. Kronos is planning further preclinical studies to assess KB-7898’s safety and pharmacological properties…